Sandostatin Articles
Briefs: Roche deal with Chiasma; Vasella payout; FDA priority review for dolutegravir
18 February 2013
Lutathera first MNM theragnostic drug, enters Ph III in cancer patients with midgut carcinoid
20 September 2012
Novartis sells rights to Proleukin in the USA to Prometheus; gets license for vaccine from IIG; and pleads guilty over Trileptal
27 January 2010
Novartis posts 50% 4th-qtr 2009 profits rise and promotes drugs chief Jimenez to CEO; other top changes
26 January 2010
Novartis drug slows 69% of GI tumors
26 January 2009
77% of patients on RAD001 achieve stable pancreatic NET tumors
22 September 2008
Octreotide implant sees 6-month efficacy
10 December 2007
13 new drugs added to Japan's NHI list
19 March 2007
Expanded use for Novartis' Sandostatin LAR in UK
5 July 2004
Novartis' Sandostatin LAR OKed in Japan
3 May 2004
Novartis Compares Growth Hormone Therapies
17 June 1999
Novartis 1998 sales down on forecasts
21 January 1999
Novartis' Sandostatin LAR Depot Approved By FDA
2 December 1998
Pharma Sales Give Novartis Boost
22 October 1998
Novartis Restructures After Disappointing First Half
1 September 1998
Novartis First Half Sales Under Expectations
16 July 1998
Novartis Files NDA For Sandostatin LAR
4 June 1998
Sensus Corp On Route To Success With GHAs?
12 February 1998
Novartis Launches Sandostatin LAR In First Market
18 December 1997
Novartis Pipeline: A Good Fit But Cuts Are Expected
18 March 1996
Novartis Pipeline: A Good Fit But Cuts Are Expected
18 March 1996
Sandoz Demergers To Focus On Pharmaceuticals
3 April 1995
Sandoz' 1994 Sales Advance 11%
23 January 1995
3% Increase In Sales For Sandoz
31 October 1994
Improvement At Sandoz in 1994 1st Half
12 September 1994
SOLID VOLUME GROWTH HELPS SANDOZ' SALES
25 July 1994
OCTREOSCAN APPROVED IN USA
13 June 1994
PHARMA SALES DRIVE SANDOZ IN 1993
31 January 1994
SUSTAINABLE EARNINGS GROWTH FOR SANDOZ
16 August 1993
SANDOZ POSTS STRONG NET INCOME
26 July 1993
MALLINCKRODT'S OCTREOSCAN
7 June 1993
BREAST CANCER US RESEARCH UPDATE
26 April 1993
1992 NET PROFITS SURGE 34% AT SANDOZ
5 April 1993
NDA FOR MALLINCKRODT
2 November 1992
THERAPEUTIC PEPTIDE MARKET
6 July 1992
SANDOSTATIN IN DIABETES
20 January 1992
Showing 1-50 of 50 articles
- 1
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
